The Central Role of Wear Debris in Periprosthetic Osteolysis

HSS Journal - Tập 2 Số 2 - Trang 102-113 - 2006
P. Edward Purdue1, Panagiotis Koulouvaris1, Bryan J. Nestor1, Thomas P. Sculco1
1Osteolysis Research Laboratory, Hospital for Special Surgery, 535 East 70th Street, 10021, New York, NY, USA

Tóm tắt

Periprosthetic osteolysis remains the leading complication of total hip arthroplasty, often resulting in aseptic loosening of the implant, and a requirement for revision surgery. Wear-generated particular debris is the main cause of initiating this destructive process. The purpose of this article is to review recent advances in our understanding of how wear debris causes osteolysis, and emergent strategies for the avoidance and treatment of this disease. The most important cellular target for wear debris is the macrophage, which responds to particle challenge in two distinct ways, both of which contribute to increased bone resorption. First, it is well known that wear debris activates proinflammatory signaling, which leads to increased osteoclast recruitment and activation. More recently, it has been established that wear also inhibits the protective actions of antiosteoclastogenic cytokines such as interferon gamma, thus promoting differentiation of macrophages to bone-resorbing osteoclasts. Osteoblasts, fibroblasts, and possibly lymphocytes may also be involved in responses to wear. At a molecular level, wear particles activate MAP kinase cascades, NFκB and other transcription factors, and induce expression of suppressors of cytokine signaling. Strategies to reduce osteolysis by choosing bearing surface materials with reduced wear properties (such as metal-on-metal) should be balanced by awareness that reducing particle size may increase biological activity. Finally, although therapeutic agents against proinflammatory mediators [such as tumor necrosis factor (TNF)] and osteoclasts (bisphosphonates and molecules blocking RANKL signaling) have shown promise in animal models, no approved treatments are yet available to osteolysis patients. Considerable efforts are underway to develop such therapies, and to identify novel targets for therapeutic intervention.

Từ khóa


Tài liệu tham khảo

10.1054/arth.2002.33664

10.2106/00004623-199274060-00006

10.1002/(SICI)1097-4636(199606)31:2<257::AID-JBM13>3.0.CO;2-I

10.2106/00004623-199411000-00010

10.1002/jor.1100180602

10.2106/00004623-200202000-00011

10.1016/S0002-9440(10)65266-2

10.1016/S0142-9612(01)00134-X

10.1002/jbm.b.30120

10.1038/sj.gt.3302192

10.2106/00004623-199608000-00008

10.2106/00004623-199905000-00002

10.1302/0301-620X.83B2.0830278

10.1016/S0142-9612(99)00261-6

10.1002/jor.1100180322

10.1002/jbm.b.30150

10.1016/j.orthres.2003.10.022

10.1002/jemt.10106

10.1006/cyto.2000.0753

10.1302/0301-620X.80B3.0800531

10.1016/S0883-5403(05)80080-4

10.1302/0301-620X.85B8.12799

10.1302/0301-620X.80B5.0800912

10.1302/0301-620X.80B4.0800694

10.1002/1097-4636(20001215)52:4<613::AID-JBM5>3.0.CO;2-8

10.1016/S0142-9612(03)00056-5

10.1016/S0142-9612(98)00140-9

10.1016/S0142-9612(02)00032-7

10.1002/jbm.820280111

10.1302/0301-620X.84B2.0840295

10.2106/00004623-200104000-00004

10.1016/S0736-0266(02)00150-X

10.1016/S8756-3282(01)00658-5

10.1002/jbm.a.20098

10.1002/jbm.820240408

10.1002/jor.1100120111

Nagase M, 1990, Nippon Seikeigeka Gakkai Zasshi, 64, 602

10.1007/PL00000313

10.1002/jor.1100180321

10.1359/jbmr.2001.16.2.338

10.1002/art.10227

10.1359/jbmr.2001.16.4.660

10.1016/j.orthres.2004.10.004

10.1073/pnas.96.7.3540

10.1042/CS19990355

10.1210/endo.139.10.6331

10.1016/S0092-8674(00)80209-3

10.1001/jama.292.4.490

10.2106/00004623-200208000-00017

10.1016/S0736-0266(01)00083-3

10.1359/jbmr.2002.17.2.192

10.1016/j.biomaterials.2004.05.017

10.1302/0301-620X.85B8.13311

10.1080/03009740310003929

10.1302/0301-620X.83B6.0830902

10.1007/s00774-003-0493-8

10.1038/35046102

Rakshit DS, 2006, J Bone Jt Surg Am, 88, 788

10.1136/ard.56.7.414

10.1302/0301-620X.81B1.0810155

10.1016/j.biomaterials.2004.01.003

10.1359/jbmr.040910

10.1002/(SICI)1097-4636(19970605)35:3<399::AID-JBM14>3.0.CO;2-A

10.1007/s004020050475

10.1016/S0883-5403(05)80152-4

10.2106/00004623-200102000-00007

10.2106/00004623-199701000-00011

10.1359/jbmr.2000.15.9.1756

10.1002/jbm.10218

10.1007/s002239900445

10.1016/S0736-0266(02)00076-1

10.1016/S0736-0266(02)00241-3

10.1016/j.biomaterials.2004.01.053

10.1359/jbmr.2000.15.8.1459

10.1359/JBMR.050206

10.1016/j.orthres.2004.10.006

10.1002/jbmr.5650100920

10.1002/jor.1100140317

10.1016/S0736-0266(01)00003-1

10.1002/1529-0131(200105)44:5<1003::AID-ANR179>3.0.CO;2-#

10.1002/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P

10.1038/46303

10.1002/1097-4636(20010605)55:3<433::AID-JBM1033>3.0.CO;2-N

10.1002/jbm.a.10200

10.1016/S0142-9612(02)00059-5

10.1080/00016470152846556

10.2106/00004623-199511000-00003

10.3109/17453679408995425

10.1016/j.orthres.2004.08.023

Sandhu J, 1998, J Rheumatol, 25, 1794

10.2106/00004623-200112000-00004

10.1016/j.orthres.2004.09.001

10.2106/00004623-200501000-00005

10.1002/1097-4636(200101)54:1<12::AID-JBM2>3.0.CO;2-X

10.1302/0301-620X.72B6.2246301

10.1084/jem.189.9.1497

10.1016/S0736-0266(01)00147-4

10.1002/(SICI)1097-4636(19980905)41:3<371::AID-JBM5>3.0.CO;2-9

10.1002/jbm.a.10477

10.1182/blood.V95.12.3868

10.1182/blood.V97.10.2932

10.1016/S0736-0266(03)00081-0

10.1038/nature01658

10.1038/nm1197-1285

10.1101/gad.11.24.3482

10.1016/S0736-0266(03)00156-6

10.1016/S0736-0266(03)00130-X

10.1359/jbmr.2003.18.9.1573

10.1038/nri1226

10.1073/pnas.95.19.11107

10.4049/jimmunol.165.9.5227

10.1038/ni1012

10.1302/0301-620X.80B3.0800377

10.1054/arth.2001.20540

10.1054/arth.2001.28376

10.2106/00004623-200404000-00012

10.1097/00003086-200512000-00024

Engh CA, 2005, Instr Course Lect, 54, 183

Capello WN, 2005, Instr Course Lect, 54, 171

10.5435/00124635-199807000-00001

10.1097/01.blo.0000193813.08458.e2

10.1097/01.blo.0000193809.85587.f8

10.2106/00004623-200107000-00012

10.1016/S0736-0266(03)00093-7

10.1016/j.biomaterials.2004.06.010

10.1016/j.biomaterials.2004.09.043

10.1359/jbmr.2005.20.12.2274

Takahashi N, 2005, Clin Calcium, 15, 43

10.1002/art.11487

10.1074/jbc.C400258200

10.1021/bi991193+

10.1016/S8756-3282(02)00675-0

10.1172/JCI6145

10.1359/jbmr.2001.16.2.319

Shakespeare WC, 2003, Curr Opin Drug Discov Dev, 6, 729

10.2106/00004623-200409000-00013

10.1186/ar384

10.2106/00004623-200204000-00016

Thông tin
Thông tin xuất bản

HSS Journal

Tập 2 Số 2

102-113

Thông tin tác giả